Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Change in Receivables (2023 - 2025)

Monte Rosa Therapeutics (GLUE) has 3 years of Change in Receivables data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Change in Receivables rose 153.78% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $4.4 million, up 925.82%, while the annual FY2024 figure was -$332000.0, 82.5% up from the prior year.
  • Change in Receivables reached $4.8 million in Q3 2025 per GLUE's latest filing, up from -$1.2 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $9.0 million in Q2 2024 and bottomed at -$8.9 million in Q3 2024.
  • Average Change in Receivables over 3 years is $233000.0, with a median of $10000.0 recorded in 2024.
  • Peak YoY movement for Change in Receivables: tumbled 299.01% in 2024, then soared 12250.0% in 2025.
  • A 3-year view of Change in Receivables shows it stood at $336000.0 in 2023, then plummeted by 225.6% to -$422000.0 in 2024, then surged by 1235.55% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $4.8 million in Q3 2025, -$1.2 million in Q2 2025, and $1.2 million in Q1 2025.